Abstract
The treatment of patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase chromosomal rearrangements has been revolutionized by the development of tyrosine kinase inhibitors (TKIs). Excellent progress has been made over the past decade, with 4 TKIs now approved in the front-line setting. Alectinib is the preferred first-line option based on its efficacy and side-effect profile. The central nervous system (CNS) activity of alectinib and brigatinib has allowed for treatment of CNS metastases with TKI therapy. Once resistance inevitably develops, newer therapies such as lorlatinib can be considered.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 137-146 |
| Number of pages | 10 |
| Journal | Thoracic surgery clinics |
| Volume | 30 |
| Issue number | 2 |
| DOIs | |
| State | Published - May 1 2020 |
| Externally published | Yes |
Keywords
- Alectinib
- Anaplastic lymphoma kinase (ALK)
- Brigatinib
- Ceritinib
- Crizotinib
- Lorlatinib
- Non–small cell lung cancer
ASJC Scopus subject areas
- Surgery
- Pulmonary and Respiratory Medicine
Fingerprint Dive into the research topics of 'Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer'. Together they form a unique fingerprint.
Cite this
Serritella, A. V., & Bestvina, C. M. (2020). Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer. Thoracic surgery clinics, 30(2), 137-146. https://doi.org/10.1016/j.thorsurg.2019.12.001